Phase I data on SLN-124 support ongoing evaluation in patients with thalassemia and MDS May 19, 2021 No Comments
An alternative to C5 inhibitors, Apellis’ pegcetacoplan wins FDA approval in PNH May 17, 2021 By Lee Landenberger No Comments Now that Apellis Pharmaceuticals Inc.’s Empaveli pegcetacoplan has won FDA approval as the first targeted C3 therapy for treating paroxysmal nocturnal hemoglobinuria (PNH), the cost of treating the rare blood disorder is hefty.Read More
FDA approves Ferriprox to treat transfusional iron overload due to sickle cell disease May 3, 2021 No Comments
Hillhurst cleared by FDA to begin phase I study of HBI-002 for sickle cell disease April 28, 2021 No Comments
Fulcrum Therapeutics' FTX-6058 could be a disease-modifying treatment for sickle cell disease April 26, 2021 No Comments